Brought to you by 
Ambrx raises $45mm in late-stage financing round
05 Aug 2016
Executive Summary
Ambrx Inc. (protein therapeutics known as bio-conjugates) raised $45mm in a late-stage financing round led by Apricot Capital and Northeast Securities Prosperity Healthcare Fund. Sinopharm Capital, Humanwell Healthcare Fund, and existing investors Fosun Pharma, HOPU Investments, and Everbright Limited Healthcare Fund also participated. The company will use the funds to further develop its Phase I asset ARX788 along with its pipeline of ADC candidates and lead immuno-oncology program CD3-folate. After withdrawing from its planned IPO in June 2014, the company was acquired by a consortium consisting of entities affiliated with Shanghai Fosun Pharmaceutical Group Co. Ltd., HOPU Investments, China Everbright Ltd.'s CEL Healthcare Fund, and WuXi PharmaTech Inc.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Synthesis Technologies, Production Processes
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ambrx raises $45mm in late-stage financing round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice